Lupin and Zentiva partner to commercialize biosimilar Certolizumab Pegol globally, sharing profits and development responsibilities.

• Lupin handles development, manufacturing, and US/Canada commercialization; Zentiva leads efforts in Europe and CIS markets.
• The agreement includes $10 million upfront and up to $50 million in milestone payments for Lupin.
• Partnership targets global access to affordable, high-quality biosimilar therapy for autoimmune diseases.